CN110382499A - Fgfr抑制剂及其应用 - Google Patents
Fgfr抑制剂及其应用 Download PDFInfo
- Publication number
- CN110382499A CN110382499A CN201880013847.XA CN201880013847A CN110382499A CN 110382499 A CN110382499 A CN 110382499A CN 201880013847 A CN201880013847 A CN 201880013847A CN 110382499 A CN110382499 A CN 110382499A
- Authority
- CN
- China
- Prior art keywords
- base
- pyrido
- chloro
- pyrimidine
- dimethoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
一种作为成纤维细胞生长因子受体(FGFR)抑制剂的氮杂三环类化合物(如式Ⅰ所示),及其药物组合物、制备方法,以及其在治疗FGFR介导的疾病中的用途。氮杂三环类化合物通过参与调节细胞增殖、凋亡、迁移、新生血管生成等多个过程而发挥作用。
Description
PCT国内申请,说明书已公开。
Claims (43)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2017/074967 | 2017-02-27 | ||
CN2017074967 | 2017-02-27 | ||
PCT/CN2018/077314 WO2018153373A1 (zh) | 2017-02-27 | 2018-02-27 | Fgfr抑制剂及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110382499A true CN110382499A (zh) | 2019-10-25 |
CN110382499B CN110382499B (zh) | 2023-01-03 |
Family
ID=63253115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880013847.XA Active CN110382499B (zh) | 2017-02-27 | 2018-02-27 | Fgfr抑制剂及其应用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11365196B2 (zh) |
EP (1) | EP3587419A4 (zh) |
JP (1) | JP6876833B2 (zh) |
KR (1) | KR20190126344A (zh) |
CN (1) | CN110382499B (zh) |
AU (1) | AU2018226315B2 (zh) |
CA (1) | CA3054455C (zh) |
RU (1) | RU2745035C1 (zh) |
SG (1) | SG11201907909TA (zh) |
TW (1) | TWI741155B (zh) |
WO (1) | WO2018153373A1 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3705480B1 (en) * | 2017-10-30 | 2024-02-28 | Shanghai Ringene BioPharma Co., Ltd. | Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof |
CN110857300B (zh) * | 2018-08-23 | 2021-11-05 | 上海凌达生物医药有限公司 | 一类稠环三氮唑类化合物、制备方法和用途 |
WO2020043078A1 (zh) * | 2018-08-27 | 2020-03-05 | 贝达药业股份有限公司 | 新型氮杂三环类化合物的盐型、晶型及其用途 |
KR102328435B1 (ko) * | 2018-09-11 | 2021-11-18 | 재단법인 대구경북첨단의료산업진흥재단 | 신규 피리도-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
US20220002307A1 (en) * | 2018-09-27 | 2022-01-06 | Betta Pharmaceuticals Co., Ltd | Fgfr4 inhibitor and use thereof |
KR20210131369A (ko) * | 2019-03-08 | 2021-11-02 | 쇼우야오 홀딩스 (베이징) 코., 엘티디. | Fgfr4 키나아제 억제제 및 이의 제조 방법과 용도 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021018003A1 (zh) * | 2019-07-26 | 2021-02-04 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
US20220259235A1 (en) * | 2019-07-26 | 2022-08-18 | Betta Pharmaceuticals Co., Ltd | EGFR Inhibitor, Composition, and Preparation Method Therefor |
TW202128173A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4130004A4 (en) * | 2020-03-27 | 2024-04-10 | Betta Pharmaceuticals Co Ltd | SALT AND CRYSTALLINE FORMS OF FGFR4 INHIBITOR AND THEIR USES |
IL302807A (en) | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | GCN2 and PERK kinase inhibitors and methods of using them |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2929414A1 (de) * | 1979-07-20 | 1981-02-05 | Hoechst Ag | Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung |
US4666812A (en) * | 1985-01-26 | 1987-05-19 | Hoechst Aktiengesellschaft | Electrophotographic material with pyrimido-pyridobenzimidazole compound |
CN1646529A (zh) * | 2002-04-03 | 2005-07-27 | 霍夫曼-拉罗奇有限公司 | 咪唑并稠合化合物 |
EP2543372A1 (en) * | 2011-07-08 | 2013-01-09 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for the treatment of liver cancer |
WO2013007708A1 (en) * | 2011-07-08 | 2013-01-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for treatment of liver cancer |
CN105481858A (zh) * | 2014-10-11 | 2016-04-13 | 上海医药集团股份有限公司 | 一种含氮稠杂环化合物、其制备方法、组合物及应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2417942C (en) * | 2000-08-04 | 2010-06-29 | Warner-Lambert Company | 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones |
WO2006019965A2 (en) * | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
FI3461825T3 (fi) | 2011-09-30 | 2023-08-17 | C&C Res Lab | Uusia heterosyklisiä johdannaisia ja niiden käyttöjä |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
PT3102577T (pt) * | 2014-02-07 | 2018-10-23 | Principia Biopharma Inc | Derivados de quinolona como inibidores do recetor do fator de crescimento de fibroblastos |
WO2016115412A1 (en) * | 2015-01-18 | 2016-07-21 | Newave Pharmaceutical Llc | Dual-warhead covalent inhibitors of fgfr-4 |
WO2018004258A1 (ko) * | 2016-06-28 | 2018-01-04 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
KR20180002053A (ko) | 2016-06-28 | 2018-01-05 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
-
2018
- 2018-02-27 EP EP18757942.0A patent/EP3587419A4/en not_active Withdrawn
- 2018-02-27 JP JP2019567775A patent/JP6876833B2/ja active Active
- 2018-02-27 CN CN201880013847.XA patent/CN110382499B/zh active Active
- 2018-02-27 KR KR1020197028565A patent/KR20190126344A/ko not_active Application Discontinuation
- 2018-02-27 US US16/488,899 patent/US11365196B2/en active Active
- 2018-02-27 RU RU2019129669A patent/RU2745035C1/ru active
- 2018-02-27 TW TW107106654A patent/TWI741155B/zh active
- 2018-02-27 CA CA3054455A patent/CA3054455C/en active Active
- 2018-02-27 WO PCT/CN2018/077314 patent/WO2018153373A1/zh active Application Filing
- 2018-02-27 SG SG11201907909TA patent/SG11201907909TA/en unknown
- 2018-02-27 AU AU2018226315A patent/AU2018226315B2/en not_active Ceased
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2929414A1 (de) * | 1979-07-20 | 1981-02-05 | Hoechst Ag | Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung |
US4666812A (en) * | 1985-01-26 | 1987-05-19 | Hoechst Aktiengesellschaft | Electrophotographic material with pyrimido-pyridobenzimidazole compound |
CN1646529A (zh) * | 2002-04-03 | 2005-07-27 | 霍夫曼-拉罗奇有限公司 | 咪唑并稠合化合物 |
EP2543372A1 (en) * | 2011-07-08 | 2013-01-09 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for the treatment of liver cancer |
WO2013007708A1 (en) * | 2011-07-08 | 2013-01-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for treatment of liver cancer |
CN105481858A (zh) * | 2014-10-11 | 2016-04-13 | 上海医药集团股份有限公司 | 一种含氮稠杂环化合物、其制备方法、组合物及应用 |
Also Published As
Publication number | Publication date |
---|---|
CA3054455C (en) | 2021-10-26 |
KR20190126344A (ko) | 2019-11-11 |
RU2745035C1 (ru) | 2021-03-18 |
WO2018153373A1 (zh) | 2018-08-30 |
CN110382499B (zh) | 2023-01-03 |
TW201831483A (zh) | 2018-09-01 |
EP3587419A4 (en) | 2020-08-05 |
JP2020509089A (ja) | 2020-03-26 |
AU2018226315B2 (en) | 2021-01-28 |
TWI741155B (zh) | 2021-10-01 |
US20210130353A1 (en) | 2021-05-06 |
EP3587419A1 (en) | 2020-01-01 |
US11365196B2 (en) | 2022-06-21 |
JP6876833B2 (ja) | 2021-05-26 |
SG11201907909TA (en) | 2019-09-27 |
CA3054455A1 (en) | 2018-08-30 |
AU2018226315A1 (en) | 2019-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110382499A (zh) | Fgfr抑制剂及其应用 | |
CN104024233B (zh) | 通过fgfr激酶的抑制抗癌的苯并吡嗪类化合物 | |
CN103370314B (zh) | 作为用于治疗癌症疾病的fgfr激酶抑制剂的取代苯并吡嗪衍生物 | |
WO2020239077A1 (zh) | 含氮杂环类衍生物调节剂、其制备方法和应用 | |
CN104910148B (zh) | 氨基三唑并吡啶和其作为激酶抑制剂的用途 | |
CN103214483B (zh) | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 | |
TWI545122B (zh) | 吡唑喹噁啉激酶抑制劑 | |
KR102134204B1 (ko) | 신규 화합물 | |
TW201930292A (zh) | 作為變構shp2抑制劑的吡啶、吡嗪和三嗪化合物 | |
CN106164076B (zh) | 作为ros1抑制剂的化合物 | |
TW201609705A (zh) | 做為週期素依賴型激酶(cdk)抑制劑之2-h-吲唑衍生物及其醫療用途 | |
TWI736578B (zh) | 6-5元稠合唑環衍生物及其藥物組合物,以及作為藥物的應用 | |
CN103038233A (zh) | 吡啶酮和氮杂吡啶酮化合物及使用方法 | |
JP6896852B2 (ja) | Fgfr阻害剤として使用される複素環式化合物 | |
WO2021143701A1 (zh) | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 | |
CN101743242A (zh) | 用作raf激酶抑制剂的杂环化合物 | |
WO2022121914A1 (zh) | 氧代氮环类衍生物调节剂、其制备方法和应用 | |
WO2020156283A1 (zh) | 炔基嘧啶或炔基吡啶类化合物、及其组合物与应用 | |
JP2022502438A (ja) | Fgfr4阻害剤及びその使用 | |
TW202028209A (zh) | 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物 | |
WO2023280237A1 (zh) | 一种磷酸酶降解剂的合成和应用 | |
TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
JP2022511236A (ja) | 置換キナゾリノン誘導体、及びmGluR4のポジティブアロステリック調節剤としてのその使用 | |
WO2023036252A1 (zh) | 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途 | |
WO2019223777A1 (zh) | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40009843 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |